Advertisement
The Food & Drug Administration issued a Public Health Advisory on Fridaywarning nursing mothers about the potential negative effects of codeine whilenursing. The advisory is posted athttp://www.fda.gov/cder/drug/advisory/codeine.htm.
Advertisement
Roche Diagnostics is the only company that makes an FDA-cleared test fordetermining a patients' CYP2D6 genotype, which helps a doctor predict howpatients will metabolize certain drugs, including codeine.
The AmpliChip test analyzes variations in two genes -- CYP2D6 and CYP2C19-- that play a primary role in the metabolism of some drugs used to treatsevere depression, schizophrenia, bi-polar disorder, cardiovascular diseasetreated with beta-blockers, attention deficit/hyperactivity disorder (ADHD)and others.
Knowledge of these gene variations can be used to help individualize drugtreatment through selection of the more appropriate drugs and adjustment ofdosages. These measures have the potential to improve patient outcome byreducing adverse drug reactions and improving drug efficacy.
For a list of laboratories offering AmpliChip CYP450 Test, go tohttp://amplichip.us.
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world's leadingresearch-focused healthcare groups in the fields of pharmaceuticals anddiagnostics. As a supplier of innovative products and services for the earlydetection, prevention, diagnosis and treatment of diseases, the Groupcontributes on a broad range of fronts to improving people's health andquality of life. Roche is a world leader in diagnostics, the leading supplierof drugs for cancer and transplantation and a market leader in virology. In2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs,and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Rocheemploys roughly 75,000 people in 150 countries and has R&D agreements andstrategic alliances with numerous partners, including majority ownershipinterests in Genentech and Chugai. Roche's Diagnostics Division offers auniquely broad product portfolio and supplies a wide array of innovativetesting products and services to researchers, physicians, patients, hospitalsand laboratories world-wide. For further information, please visit our U.S.website at www.roche-diagnostics.us.
All trademarks used or mentioned in this release are legally protected bylaw.For further information please contact: Lori McLaughlin Corporate Communication Roche Diagnostics Corporation, Indianapolis, Ind. Phone: 317-521-3112 [email protected]
SOURCE Roche Diagnostics
